Profile of the procedure:
- From female unfertilized ova (so-called parthenogene) stem cells are obtained and further developed into neuronal stem cells (a precursor of dopamine-producing brain cells) and subsequently implanted in the substantia nigra of Parkinson's patients.
- According to current knowledge, these cells are tolerated by the immune system of the implant recipient without rejection.
- The company "International Stem Cell Corporation (ISCO)" has completed the necessary basic research and the necessary animal experiments with considerable success. In transplantation trials with Parkinson's disease patients, a substantial reduction in Parkinson's symptoms and a restoration of the animals' ability to move could be achieved.
- Currently, ISCO is seeking the approval test for clinical use in humans (see hier ).
Links to ISCO:
The method used: